SANTORO, MASSIMO
SANTORO, MASSIMO
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer
2017 De Falco V.; Carlomagno F.; Li H.Y.; Santoro M.
A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.
2016 Cantisani, Mc; Parascandolo, A; Perälä, M; Allocca, C; Fey, V; Sahlberg, N; Merolla, F; Basolo, F; Laukkanen, Mo; Kallioniemi, Op; Santoro, M; Castellone, Md
Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma
2015 Castellone M.D.; Laukkanen M.O.; Teramoto H.; Bellelli R.; Ali G.; Fontanini G.; Santoro M.; Gutkind J.S.
Genetics: The genomic landscape of papillary thyroid carcinoma
2015 Santoro, Massimo; Melillo Rosa, M
Identification of novel small molecule inhibitors of oncogenic RET kinase
2015 Moccia, M; Liu, Q; Guida, T; Federico, G; Brescia, A; Zhao, Z; Choi, Hg; Deng, X; Tan, L; Wang, J; Billaud, M; Gray, Ns; Carlomagno, F; Santoro, M
Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.
2015 Visciano, C; Liotti, F; Prevete, N; Cali', G; Franco, R; Collina, F; de Paulis, A; Marone, G; Santoro, M; Melillo, Rm
Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies
2014 Bossi D.; Carlomagno F.; Pallavicini I.; Pruneri G.; Trubia M.; Raviele P.R.; Marinelli A.; Anaganti S.; Cox M.C.; Viale G.; Santoro M.; Di Fiore P.P.; Minucci S.
Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation
2014 Frett, B; Moccia, M; Carlomagno, F; Santoro, M; Li, Hy
Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment
2014 Moretti S.; Menicali E.; Voce P.; Morelli S.; Cantarelli S.; Sponziello M.; Colella R.; Fallarino F.; Orabona C.; Alunno A.; De Biase D.; Bini V.; Mameli M.G.; Filetti S.; Gerli R.; Macchiarulo A.; Melillo R.M.; Tallini G.; Santoro M.; Puccetti P.; Avenia N.; Puxeddu E.
NCOA4 transcriptional coactivator inhibits activation of DNA replication origins.
2014 Bellelli R; Castellone MD; Guida T; Limongello R; Dathan NA; Merolla F; Cirafici AM; Affuso A; Masai H; Costanzo V; Grieco D; Fusco A; Santoro M; Carlomagno F.
Attacking cancer with molecularly targeted agents Editorial overview
2013 Santoro, M; Carlomagno, F
Central role of RET in thyroid cancer
2013 Santoro M.; Carlomagno F.
Oncogenic rearrangements driving ionizing radiation-associated human cancer
2013 Santoro M.; Carlomagno F.
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
2013 De Falco, V; Buonocore, P; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, F; Santoro, M
Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis.
2013 Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A.
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts.
2012 Faraonio, R; Salerno, P; Passaro, F; Sedia, C; Iaccio, A; Bellelli, R; Nappi, Tc; Comegna, M; Romano, S; Salvatore, G; Santoro, M; Cimino, F
Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
2012 Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA Jr; Santoro M.
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells.
2012 De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M.
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model.
2012 Ward Y; Lake R; Martin PL; Killian K; Salerno P; Wang T; Meltzer P; Merino M; Cheng SY; Santoro M; GarciaRostan G; Kelly K.
CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.
2012 Torregrossa, L; Giannini, R; Borrelli, N; Sensi, E; Melillo, Rm; Leocata, P; Materazzi, G; Miccoli, P; Santoro, M; Basolo, F
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer | 1-gen-2017 | De Falco V.; Carlomagno F.; Li H.Y.; Santoro M. | |
| A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability. | 1-gen-2016 | Cantisani, Mc; Parascandolo, A; Perälä, M; Allocca, C; Fey, V; Sahlberg, N; Merolla, F; Basolo, F; Laukkanen, Mo; Kallioniemi, Op; Santoro, M; Castellone, Md | |
| Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma | 1-gen-2015 | Castellone M.D.; Laukkanen M.O.; Teramoto H.; Bellelli R.; Ali G.; Fontanini G.; Santoro M.; Gutkind J.S. | |
| Genetics: The genomic landscape of papillary thyroid carcinoma | 1-gen-2015 | Santoro, Massimo; Melillo Rosa, M | |
| Identification of novel small molecule inhibitors of oncogenic RET kinase | 1-gen-2015 | Moccia, M; Liu, Q; Guida, T; Federico, G; Brescia, A; Zhao, Z; Choi, Hg; Deng, X; Tan, L; Wang, J; Billaud, M; Gray, Ns; Carlomagno, F; Santoro, M | |
| Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. | 1-gen-2015 | Visciano, C; Liotti, F; Prevete, N; Cali', G; Franco, R; Collina, F; de Paulis, A; Marone, G; Santoro, M; Melillo, Rm | |
| Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies | 1-gen-2014 | Bossi D.; Carlomagno F.; Pallavicini I.; Pruneri G.; Trubia M.; Raviele P.R.; Marinelli A.; Anaganti S.; Cox M.C.; Viale G.; Santoro M.; Di Fiore P.P.; Minucci S. | |
| Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation | 1-gen-2014 | Frett, B; Moccia, M; Carlomagno, F; Santoro, M; Li, Hy | |
| Indoleamine 2,3-Dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment | 1-gen-2014 | Moretti S.; Menicali E.; Voce P.; Morelli S.; Cantarelli S.; Sponziello M.; Colella R.; Fallarino F.; Orabona C.; Alunno A.; De Biase D.; Bini V.; Mameli M.G.; Filetti S.; Gerli R.; Macchiarulo A.; Melillo R.M.; Tallini G.; Santoro M.; Puccetti P.; Avenia N.; Puxeddu E. | |
| NCOA4 transcriptional coactivator inhibits activation of DNA replication origins. | 1-gen-2014 | Bellelli R; Castellone MD; Guida T; Limongello R; Dathan NA; Merolla F; Cirafici AM; Affuso A; Masai H; Costanzo V; Grieco D; Fusco A; Santoro M; Carlomagno F. | |
| Attacking cancer with molecularly targeted agents Editorial overview | 1-gen-2013 | Santoro, M; Carlomagno, F | |
| Central role of RET in thyroid cancer | 1-gen-2013 | Santoro M.; Carlomagno F. | |
| Oncogenic rearrangements driving ionizing radiation-associated human cancer | 1-gen-2013 | Santoro M.; Carlomagno F. | |
| Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. | 1-gen-2013 | De Falco, V; Buonocore, P; Muthu, M; Torregrossa, L; Basolo, F; Billaud, M; Gozgit, Jm; Carlomagno, F; Santoro, M | |
| Tumour Suppressor Role of the CL2/DRO1/CCDC80 Gene in Thyroid Carcinogenesis. | 1-gen-2013 | Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A. | |
| A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. | 1-gen-2012 | Faraonio, R; Salerno, P; Passaro, F; Sedia, C; Iaccio, A; Bellelli, R; Nappi, Tc; Comegna, M; Romano, S; Salvatore, G; Santoro, M; Cimino, F | |
| Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. | 1-gen-2012 | Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA Jr; Santoro M. | |
| CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. | 1-gen-2012 | De Falco V; Tamburrino A; Ventre S; Castellone MD; Malek M; Manié SN; Santoro M. | |
| CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. | 1-gen-2012 | Ward Y; Lake R; Martin PL; Killian K; Salerno P; Wang T; Meltzer P; Merino M; Cheng SY; Santoro M; GarciaRostan G; Kelly K. | |
| CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. | 1-gen-2012 | Torregrossa, L; Giannini, R; Borrelli, N; Sensi, E; Melillo, Rm; Leocata, P; Materazzi, G; Miccoli, P; Santoro, M; Basolo, F |